TWiV reveals how treatment with remdesivir for COVID-19 resolved a chronic poliovirus infection in an immunocompromised patient, and the finding that infection with SARS-CoV-2 leads to an increase in new and preexisting autoantibodies.
TWiV Special: One COVID vaccine for them all with Paul Offit
- February 3, 2023
- Tagged as: bivalent booster, coronavirus, COVID-19, Omicron, pandemic, SARS-CoV-2, Vaccine, viral, virology, virus, viruses, VRBPAC
Paul Offit returns to TWiV to unpack the recent FDA Advisory Panel on COVID vaccines, with discussions on giving everyone the same bivalent vaccine, simplifying the immunization schedule, and how to know when the vaccine should be updated.
TWiV 969: Carl Zimmer on COVID-19
- December 28, 2022
- Tagged as: coronavirus, COVID-19, pandemic, public health, SARS-CoV-2, Vaccine, viral, virology, virus, viruses
Carl Zimmer visits the Incubator to record a wide-ranging conversation about COVID-19, including origins, vaccines, public health responses, and impact on society.
TWiV 952: Jake Scott put the ID in COVID-19
- November 6, 2022
- Tagged as: antiviral, coronavirus, COVID-19, pandemic, SARS-CoV-2, Vaccine, viral, virology, virus, viruses
Infectious Disease physician Jake Scott joins TWiV to provide a west coast clinical perspective on the evolution of the COVID-19 pandemic with respect to the impact of vaccines, antivirals, variants of concern and mortality.
In COVID-19 clinical update #124, Dr. Griffin discusses the results of a variant vaccine booster trial, the neutralization of variant sub-lineages by Novavax, the CDC’s recommendation of Novavax’s COVID-19 vaccine in adults, Paxlovid in patients who are immunocompromised and hospitalized, and inhaled fluticasone for outpatient treatment.
In COVID-19 clinical update #123, Dr. Griffin discusses rapid diagnostic testing in response to the monkeypox outbreak, leading causes of death in the US during the COVID-19 pandemic, antibody evasion by subvariants, broadly-neutralizing antibodies against emerging variants, factors associated with severe outcomes among hospitalized immunocompromised adults, measurement of the burden of hospitalizations during the pandemic, parental vaccine hesitancy in diverse communities, evaluating saliva sampling to improve access to diagnosis in low-resource settings, oral sabizabulin for high-risk hospitalized adults, lower-risk of multisystem inflammatory syndrome in children, and neurovascular injury with complement activation and inflammation during infection.
TWiV 916: COVID-19 clinical update #122 with Dr. Daniel Griffin
- July 9, 2022
- Tagged as: antiviral, coronavirus, COVID-19, delta, inflammation, long COVID, monoclonal antibody, Omicron, pandemic, SARS-CoV-2, Vaccine, vaccine booster, variant of concern, viral, virology, virus, viruses
In COVID-19 clinical update #122, Dr. Griffin discusses vaccine availability and coverage among children, post-infection health impairments in children and adolescents, infection detection using salvia and nasopharyngeal samples, effectiveness of vaccines during delta dominance, durability…
TWiV 914: COVID-19 clinical update #121 with Dr. Daniel Griffin
- July 2, 2022
- Tagged as: antiviral, coronavirus, COVID-19, delta, inflammation, long COVID, monoclonal antibody, Omicron, pandemic, SARS-CoV-2, Vaccine, vaccine booster, variant of concern, viral, virology, virus, viruses
In COVID-19 clinical update #121, Dr. Griffin discusses age as a risk factor for severe disease, updated vaccine boosters for the fall, pediatric infection and antibody seroprevalence in Arkansas over the first year of the COVID-19 pandemic, all-cause maternal mortality in the United States before and during the pandemic, and the effect of 2-week interruption in methotrexate treatment and how it impacts vaccine immunity.
In COVID-19 clinical update #120, Dr. Griffin discusses outcomes of SARS-CoV-2 reinfection, CDC recommendation for vaccines in young children, neurodevelopment outcomes in infants of mothers testing positive for COVID during pregnancy, efficacy of monoclonal antibodies and antivirals in hamsters, rebound phenomenon after PAXLOVID in high-risk persons, hospitalization for infection after PAXLOVID treatment, and risk of long COVID with different variants.
In COVID-19 clinical update #119, Dr. Griffin reviews tixagevimab for infection prevention, ivermectin for outpatient infection treatment, symptom rebound after PAXLOVID treatment, bamlanivimab minimally impacting immune response to vaccination, in-hospital mortality among infection patients, residual viral antigen in patients following infection, usage of Casirvimab/Imdevimab and Remdesivir in infected patients with depleted B-cells, and rheumatic symptoms following infection.